



(11)

EP 3 490 574 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(51) International Patent Classification (IPC):

A61K 35/76 ^(2015.01) **A61K 35/761** ^(2015.01)
A61K 35/763 ^(2015.01) **A61K 39/21** ^(2006.01)
A61K 48/00 ^(2006.01) **A61P 35/00** ^(2006.01)

(48) Corrigendum issued on:

10.07.2024 Bulletin 2024/28

(52) Cooperative Patent Classification (CPC):

A61K 35/763; A61P 35/00; C12N 9/16;
C12N 2710/16632; C12N 2710/16643

(45) Date of publication and mention
of the grant of the patent:

22.05.2024 Bulletin 2024/21

(86) International application number:

PCT/US2017/044683

(21) Application number: **17835414.8**

(87) International publication number:

WO 2018/023114 (01.02.2018 Gazette 2018/05)

(22) Date of filing: **31.07.2017**

(54) **EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES**

EXPRESSION VON PTEN-LONG MIT ONKOLYTISCHEN VIREN

EXPRESSION DE PTEN-LONG AVEC DES VIRUS ONCOLYTIQUES

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(74) Representative: **Creek, Isobel Clare**

The IP Asset Partnership Limited
Prima House
267 Banbury Road
Oxford OX2 7HT (GB)

(30) Priority: **29.07.2016 US 201662368822 P**
31.03.2017 US 201762479671 P

(56) References cited:

WO-A1-2013/169388 US-A1- 2007 092 968
US-A1- 2008 292 592 US-A1- 2012 039 861
US-A1- 2013 065 952 US-A1- 2014 065 694

(43) Date of publication of application:
05.06.2019 Bulletin 2019/23

(60) Divisional application:
24176375.4

- **ZHONG ET AL: "Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice", INTERNATIONAL JOURNAL OF NANOMEDICINE, 1 September 2012 (2012-09-01), pages 5039, XP055661684, DOI: 10.2147/IJN.S34022**
- **MIAO DING ET AL: "Prostate Cancer-Specific and Potent Antitumor Effect of a DD3-Controlled Oncolytic Virus Harboring the PTEN Gene", PLOS ONE, vol. 7, no. 4, 11 April 2012 (2012-04-11), pages e35153, XP055661553, DOI: 10.1371/journal.pone.0035153**

(73) Proprietor: **Ohio State Innovation Foundation**
Columbus, OH 43201 (US)

(72) Inventors:

- **KAUR, Balveen**
Houston
Texas 77030 (US)
- **RUSSELL, Luke**
Rochester
Minnesota 55906 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 490 574 B8

- LUKE RUSSELL ET AL: "Abstract 601: Oncolytic and immune effects of RAPTOR: a novel oncolytic Herpes Simplex Virus 1 expressing PTEN-L for brain tumor therapy", CANCER RESEARCH, vol. 77, no. Suppl. 13, 1 April 2017 (2017-04-01), pages 601, XP055661567, DOI: 10.1158/1538-7445.AM2017-601
- PALIAN, B: "MAF1 is a Novel Target of the Tumor Suppressor PTEN and a Negative Regulator of Lipid Metabolism", THESIS, UNIVERSITY OF SOUTHERN CALIFORNIA, 13 June 2012 (2012-06-13), pages 1 - 65, XP055457973, Retrieved from the Internet
<URL:http://cdm15799.contentdm.oclc.org/cdm/ref/collection/p15799coll3/id/48553> [retrieved on 20170913]
- GEORGE ET AL.: "Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma", IMMUNITY, vol. 46, no. 2, 21 February 2017 (2017-02-21), pages 197 - 204, XP029929852
- "Catalog no. V810-20", THERMOFISHER SCIENTIFIC, 9 November 2010 (2010-11-09), pages 1 - 23, XP055457982, Retrieved from the Internet
<URL:https://assets.thermofisher.com/TFS-Assets/LSG/manuals/pcdna3_1v5his_man.pdf> [retrieved on 20170913]